日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

(Giga)TIME for the era of AI: virtual multiplex immunofluorescence from routine H&E for large populations

面向人工智能时代的(Giga)TIME:基于常规H&E染色的大规模人群虚拟多重免疫荧光检测

Yang, Shao-Ping; Yu, Dihua

Exosome-Enriched Hub Gene Networks Identify Diagnostic Biomarkers and Repurposable Therapeutic Targets in Endometriosis

富含外泌体的枢纽基因网络可识别子宫内膜异位症的诊断生物标志物和可重新利用的治疗靶点

Tsai, Meng-Hsiu; Weng, Shao-Ping; Su, Li-Jen; Lai, Tsung-Hsuan

Inventory of statements about self-harm (ISAS): development and validation of a Chinese short version in a single-center sample

自残行为陈述清单(ISAS):单中心样本中中文简短版本的开发与验证

Liu, Chuan-Jian; Wu, Guo-Jiang; Mao, Chen; Xiao, Jun-Jian; Li, Ling-Yan; Xu, Shao-Ping; Xu, Meng-Xia; Liu, Li-Dan; Tian, Yang-Li; Chao, Xue-Lin; Wan, Ai-Lan; Liu, Qiao-Sheng; Luo, Tao

Neoadjuvant transarterial chemoembolization with tyrosine kinase and immune checkpoint inhibitors improves survival from resectable hepatocellular carcinoma in a multicenter, retrospective study (GUIDANCE002)

一项多中心回顾性研究(GUIDANCE002)表明,新辅助经动脉化疗栓塞联合酪氨酸激酶和免疫检查点抑制剂可提高可切除肝细胞癌患者的生存率。

Yang, Da-Long; Qin, Chuang; Peng, Ning; Liu, Shao-Ping; Yu, Ya-Qun; Nong, Jun-Liang; Zeng, Fan-Jian; Su, Ze; Yang, Yong-Yu; Yang, Fu-Quan; Li, Mian-Jing; Wu, Ming-Song; Wang, Xue-Yao; Liang, Yong-Rong; Li, Fu-Xin; Chen, Shu-Chang; Lai, Yong-Cheng; Pang, Qing-Qing; Zhong, Teng-Meng; Yan, Yi-He; Zhang, Ying-Yu; Ye, Lin; Dong, Xiao-Feng; Li, Wen-Feng; Liu, Jie; Yao, Hong-Bing; Wu, Pei-Sheng; Mao, Xian-Shuang; Ou, Jun-Jie; Chen, Yao-Zhi; Wang, Guo-Dong; Chen, Kang; Deng, Zhu-Jian; Su, Jia-Yong; Qiu, Guo-Gao; Liu, Zhi-Dong; Wang, Jin-Min; Zhang, Yi; Liang, Xiu-Mei; Xiang, Bang-De; Ma, Liang; Zhong, Jian-Hong

RNA cytidine acetyltransferase NAT10 maintains T cell pathogenicity in inflammatory bowel disease

RNA胞苷乙酰转移酶NAT10在炎症性肠病中维持T细胞致病性

Haixin Li #, Xuemin Cai #, Changfen Xu #, Xinhui Yang, Xiaohan Song, Yuxin Kong, Mei Yang, Qielan Wu, Song Guo Zheng, Yiming Shao, Ping Wang, Jing Zhou, Hua-Bing Li6

Treatment Duration of Adjuvant Immune Checkpoint Inhibitors in Hepatocellular Carcinoma Patients at High Risk of Recurrence after Resection: A Prospective, Multicentric Cohort Study

肝细胞癌切除术后复发高风险患者辅助免疫检查点抑制剂治疗持续时间:一项前瞻性多中心队列研究

Su, Jia-Yong; Liu, Shao-Ping; Xu, Xiao-Ling; Ou, Jun-Jie; Ye, Po-Hua; Zhao, Bin-Tong; Chen, Jia-Song; Luo, Qiu-Mei; Liu, Jin-Rong; Tang, Fei-Min; Li, Jian-Rong; Yang, Da-Long; Deng, Zhu-Jian; Pan, Li-Xin; Li, Yao-Jie; Li, Le; Qin, Zhen-Ming; Liang, Xiu-Mei; Ma, Yi-Li; Ma, Liang; Zhong, Jian-Hong

Survival Benefit of Hepatectomy after Complete or Partial Response to Conversion Therapy in Unresectable Hepatocellular Carcinoma (GUIDANCE003): A Multicenter Study

不可切除肝细胞癌转化治疗后完全或部分缓解行肝切除术的生存获益(GUIDANCE003):一项多中心研究

Yang, Da-Long; Peng, Ning; Nong, Jun-Liang; Chen, Kang; Su, Ze; Yu, Ya-Qun; Ye, Lin; Zeng, Fan-Jian; Liu, Shao-Ping; Yan, Yi-He; Wang, Xue-Yao; Yao, Hong-Bing; Yang, Fu-Quan; Li, Wen-Feng; Qin, Chuang; Wu, Ming-Song; Yang, Yong-Yu; Dong, Xiao-Feng; Li, Mian-Jing; Liu, Jie; Liang, Yong-Rong; Wu, Pei-Sheng; Zhong, Teng-Meng; Lai, Yong-Cheng; Chen, Yao-Zhi; Pang, Qing-Qing; Wang, Guo-Dong; Li, Fu-Xin; Mao, Xian-Shuang; Chen, Shu-Chang; Ou, Jun-Jie; Huo, Rong-Rui; Liang, Xiu-Mei; Xiang, Bang-De; Ma, Liang; Zhong, Jian-Hong

Prognostic Usefulness of Clinical Complete Response after PD-1 Inhibitor-Based Combination Therapy for Unresectable Hepatocellular Carcinoma (GUIDANCE006)

PD-1抑制剂联合疗法治疗不可切除肝细胞癌后临床完全缓解的预后价值(GUIDANCE006)

Ma, Liang; Yang, Da-Long; Zhong, Teng-Meng; Pang, Qing-Qing; Luo, Min; Li, Wen-Feng; Yan, Yi-He; Chen, Kang; Wang, Guo-Dong; Yang, Fu-Quan; Lai, Yong-Cheng; Wu, Ming-Song; Dong, Xiao-Feng; Yang, Yong-Yu; Peng, Ning; Nong, Jun-Liang; Su, Ze; Yu, Ya-Qun; Ye, Lin; Zeng, Fan-Jian; Liu, Shao-Ping; Wang, Xue-Yao; Yao, Hong-Bing; Qin, Chuang; Li, Mian-Jing; Liu, Jie; Liang, Yong-Rong; Wu, Pei-Sheng; Li, Fu-Xin; Chen, Shu-Chang; Lu, Si-Cong; Li, Zhi-Cheng; Liu, Zhen; Guo, Ping-Ping; Pan, Li-Xin; Zhong, Jian-Hong

Prognostic value of radiological and pathological complete response following immune-based conversion therapy in patients with unresectable hepatocellular carcinoma (GUIDANCE004)

放射学和病理学完全缓解对不可切除肝细胞癌患者进行免疫转化治疗的预后价值(GUIDANCE004)

Yang, Da-Long; Yan, Yi-He; Lai, Yong-Cheng; Wu, Ming-Song; Dong, Xiao-Feng; Chen, Yao-Zhi; Li, Wen-Feng; Yang, Fu-Quan; Yang, Yong-Yu; Zhong, Teng-Meng; Wang, Guo-Dong; Pang, Qing-Qing; Chen, Kang; Peng, Ning; Nong, Jun-Liang; Su, Ze; Yu, Ya-Qun; Ye, Lin; Zeng, Fan-Jian; Liu, Shao-Ping; Wang, Xue-Yao; Yao, Hong-Bing; Qin, Chuang; Zhang, Ying-Yu; Liu, Jie; Li, Mian-Jing; Liang, Yong-Rong; Wu, Pei-Sheng; Li, Fu-Xin; Mao, Xian-Shuang; Chen, Shu-Chang; Ou, Jun-Jie; Luo, Min; Lu, Si-Cong; Li, Zhi-Cheng; Huang, Shen; Su, Jia-Yong; Chen, Huan; Zhang, Yi-Ge; Liang, Xiu-Mei; Ma, Yi-Li; Ma, Liang; Zhong, Jian-Hong

The efficacy and safety of tislelizumab with or without tyrosine kinase inhibitor as adjuvant therapy in hepatocellular carcinoma with high-risk of recurrence after curative resection

替雷利珠单抗联合或不联合酪氨酸激酶抑制剂作为辅助治疗治疗根治性切除术后复发高风险肝细胞癌的疗效和安全性

Peng, Ning; Mao, Lin-Feng; Su, Jia-Yong; Liu, Shao-Ping; Ou, Jun-Jie; Chen, Shu-Chang; Su, Ze; Li, Wen-Feng; Yang, Fu-Quan; Zhou, Yong-Heng; Li, Le; Zhong, Jian-Hong